27 February 2014 Effects of cyclophosphamide on laser immunotherapy for the treatment of metastatic cancer
Author Affiliations +
Proceedings Volume 8944, Biophotonics and Immune Responses IX; 894408 (2014) https://doi.org/10.1117/12.2040954
Event: SPIE BiOS, 2014, San Francisco, California, United States
Abstract
Laser immunotherapy (LIT) is an innovative cancer modality that uses laser irradiation and immunological stimulation to treat late-stage, metastatic cancers. The current mode of operation in LIT is through interstitial laser irradiation. Although LIT is still in development, recent clinical trials have shown that it can be used to successfully treat patients with late-stage breast cancer and melanoma. Cyclophosphamide is a chemotherapy drug that suppresses regulatory T cells when used in low doses. In this study tumor-bearing rats were treated with LIT using an 805-nm laser with a power of 2.0 W and low-dose cyclophosphamide. Glycated chitosan was used as an immunological stimulant. The goal was to observe the effects of different doses of cyclophosphamide in addition to LIT on the survival of the tumor-bearing rats.
© (2014) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Cody F. Bahavar, Cody F. Bahavar, Joseph T. Acquaviva, Joseph T. Acquaviva, Sheyla Rabei, Sheyla Rabei, Allie Sikes, Allie Sikes, Robert E. Nordquist, Robert E. Nordquist, Tomas Hode, Tomas Hode, Hong Liu, Hong Liu, Wei R. Chen, Wei R. Chen, } "Effects of cyclophosphamide on laser immunotherapy for the treatment of metastatic cancer", Proc. SPIE 8944, Biophotonics and Immune Responses IX, 894408 (27 February 2014); doi: 10.1117/12.2040954; https://doi.org/10.1117/12.2040954
PROCEEDINGS
6 PAGES


SHARE
Back to Top